
Small Molecules of the Month

August 2021 drughunter.com




berotralstsat | kallikrein

Oral plasma kallikrein serine protease inhibitor Approved for prevention of HAE attacks From structure-based drug design Journal of Medicinal Chemistry BioCryst, Birmingham, AL, USA

CC-90005 | PKC0

Oral, selective PKC0 kinase inhibitor Ph. I candidate for Psoriasis From screen of internal library and SBDD Journal of Medicinal Chemistry Celgene/BMS, San Diego, CA, USA





soticlestat | CH24H

Brain-penetrant CH24H inhibitor Ph. 2 for epilepsies (up to 300 mg PO QD) From SBDD Journal of Medicinal Chemistry Takeda, Fujisawa, Japan

Oral, brain-penetrant, reversible MAGL inh.

in vivo PK/PD in CNS (0.3-10 mpk PO)






from HTS and SBDD


ZN-c3 | Wee1


Takeda, Fujisawa, Japan

"compound 4f" | MAGL


Journal of Medicinal Chemistry














"compound 20" | RIPK2

Long-acting RIPK2 degrader (SC admin.) In vivo degradation of RIPK2 over 60 days IAP binder linked to RIPK2 binder Journal of Medicinal Chemistry GlaxoSmithKline, Stevenage, UK

ASTX029 | ERK1/2

Oral ERK1/2 kinase and phosphorylation inhib. Ph. 1/2 candidate for solid tumors from SBDD from prior lead Journal of Medicinal Chemistry Astex Pharmaceuticals, Cambridge, UK

BMS-986318 | FXR

Oral FXR agonist for NASH Robust in vivo PD, phase I HV study withdrawn From prior FXR agonists ACS Med. Chem. Lett Bristol Myers Squibb, Princeton, NJ, USA

MK-8262 | CETP

Potential best-in-class CETP inh. (<1 mg QD) Completed Ph. I in HV; discont. as backup From anacetrapib Journal of Medicinal Chemistry Merck & Co., Kenilworth, NJ, USA

BAY-8400 | DNA-PK

Oral selective DNA-PK kinase inhibitor Synergy with radiotherapy in model From library screen Journal of Medicinal Chemistry Bayer AG, Berlin, Germany

TAK-020 | BTK

Oral covalent BTK inhibitor >80% BTK occupancy <5 mg (Ph. I dose esc.) From fragment-based screen of 11k cmpds Journal of Medicinal Chemistry Takeda, San Diego, CA, USA


"compound 18n" | MCT4

Monocarboxylate transporter 4 inhibitor In vivo PD but limited eff. in xenograft model From cell-based screen and opt. Journal of Medicinal Chemistry Merck Healthcare KGaA, Darmstadt, Germany



Ph. II candidate for uterine serous carcinoma From literature starting point Journal of Medicinal Chemistry Zentalis Pharmaceuticals, San Diego, CA, USA

NBI-921352 | NaV1.6



AZD0284 | RORC2

Arylsulfonamide class

bioRxiv

Oral RORC2 inverse agonist for psoriasis 100 mg PO BID, Ph. I term. due to preclin. data From opt. of lit. inverse agonist Journal of Medicinal Chemistry AstraZeneca, Gothenburg, Sweden

Highly selective NaV1.6 sodium channel inh.

Entering Ph. II for seizures (100 mg TID)

Xenon Pharmaceuticals, Burnaby, Canada

